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Especially if it is about the future.—Niels Bohr (1)R heumatoid arthritis (RA) is a common autoim-mune condition presenting with symmetricpolyarticular arthritis and affecting 0.5% to
1.0% of the population (2). It is associated with signif-
icant and progressive disability, extra-articular sys-
temic complications, high socioeconomic costs, and
early death (3). Cardiac manifestations occur in up to
60% of patients with RA and include pericarditis,
myocarditis, ischemic heart disease, and heart failure,
leading to a doubling of the cardiac mortality risk
compared with that of healthy control subjects (4).
Life expectancy is reduced by w5 to 10 years, and
35% to 50% of this excess mortality seems to result
from cardiovascular disease (5). Despite this ﬁnding,
conventional cardiac risk factors only partly explain
the increased risk, making the identiﬁcation of indi-
viduals likely to experience a future cardiac event
challenging. Detecting cardiac disease at an early
stage (before the heart is permanently damaged) has
important clinical implications because targeted phar-
macotherapy has the potential to improve prognosis.SEE PAGE 526In this issue of iJACC, Ntusi et al. (6) presentﬁndings
from a cardiac magnetic resonance (CMR) study of 39
patients with RA and no known cardiac involvement
compared with 39 matched control subjects. The
authors’ goal was to identify a novel CMR biomarker
for assessing cardiac involvement in patients with RA.
The authors should be commended for completing a
well-designed prospective study and undertaking
careful myocardial tissue characterization. Using aals published in JACC: Cardiovascular Imaging reﬂect the views of
hors and do not necessarily represent the views of JACC:
ascular Imaging or the American College of Cardiology.
he Royal Brompton Hospital and National Heart and Lung
, Imperial College London, London, United Kingdom. Dr.
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disclose.previously validated sequence (7), native and post-
contrast T1 maps were acquired, enabling calculation
of extracellular volume fraction, with T2-weighted
and late gadolinium enhancement (LGE) imaging
for identiﬁcation of edema and replacement ﬁbrosis,
respectively. In addition, routine CMR parameters
(including ventricular dimensions and volumes, ejec-
tion fractions, and myocardial strain) were acquired.
LGE is a marker of adverse prognosis in many
patient populations, including those with cardiomy-
opathy (8), valvular disease (9), coronary artery dis-
ease, and congenital heart disease (10). However,
the presence of LGE correlates histologically with
replacement ﬁbrosis; it commonly occurs late in the
disease process and is believed to be irreversible.
Because LGE relies on the differential signal in-
tensity between normal and abnormal myocardium, it
can only usually detect focal ﬁbrosis. It has a rela-
tively low sensitivity in identifying homogeneously
abnormal diffuse myocardial ﬁbrosis secondary to
progressive accumulation of collagen in the intersti-
tial space (11). The novel T1-mapping methods are
based on a modiﬁed Look-Locker sequence, as
described by Messroghli et al. (12); these methods
have emerged as promising CMR techniques that
enable the identiﬁcation of diffuse ﬁbrosis. The
importance of identifying diffuse ﬁbrosis is that it is
potentially reversible with appropriate therapy, with
a more tangible possibility for improvement in prog-
nosis (11).
Studies in this area have expanded rapidly over the
past few years, with differences in diffuse ﬁbrosis
burden seen between normal control subjects and
patients with amyloid heart disease, Fabry’s disease,
valvular heart disease, cardiomyopathy, myocardial
infarction, and other connective tissue diseases
(including systemic lupus erythematosus and sys-
temic sclerosis) (10). Importantly, the combination of
native and post-contrast T1 maps and hematocrit
enable calculation of extracellular volume (ECV)
fraction, which has correlated well with expansion in
ECV due to deposition of extracellular matrix pro-
teins, including collagen and histologically identiﬁed
diffuse ﬁbrosis (7).
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538Ntusi et al. (6) found that diffuse ﬁbrosis, focal
ﬁbrosis, and inﬂammation can all be identiﬁed reli-
ably with CMR in RA. In this study, 18 patients
with RA (46%) had evidence of LGE, mostly of
a patchy, nonischemic mid-wall pattern, although
2 patients (5%) had evidence of a previous silent
myocardial infarction; epicardial coronary disease
was conﬁrmed on subsequent coronary angiography.
There was a small difference observed in native T1
between RA patients and control subjects (973  27
ms vs. 961  18 ms; p ¼ 0.03), but, more important,
patients with RA had higher ECV than control sub-
jects (30.3  3.4% vs. 27.9  2.0 ms; p < 0.001). At
the same time, patients with RA had more areas of
focal myocardial edema within the left ventricle
(10% vs. 0%; p < 0.001), acknowledging that the
increase in ECV, in the absence of infarction, could
be either secondary to myocardial diffuse ﬁbrosis
or inﬂammation or possibly a combination of the
2 factors. Recent studies have also suggested that
independent of etiology, an increase as small as 3%
in ECV can be associated with signiﬁcantly worse
short-term outcomes in the general population and
in patients with diabetes (13). Therefore, the ﬁndings
by Ntusi et al. (6) have the potential to correctly
identify early cardiac involvement in asymptomatic
patients with RA, allowing stratiﬁcation of patients
into high- and low-risk groups. Furthermore, the
authors found that both the degree of diffuse ﬁbrosis
and inﬂammation were elevated independently of
the presence of LGE and correlated well with a
validated RA disease activity score and diastolic and
systolic myocardial strain; this supports the notion
that T1 mapping could be used independently as a
novel biomarker.
However, some limitations of the current study (6)
prevent generalization of the results at this point. The
aim is to produce a robust biomarker to predict
outcome, whether from CMR and other imaging mo-
dalities or using blood biomarkers such as high-
sensitivity troponin, B-type natriuretic peptide,
ST2 cells, transforming growth factor-beta, or
C-reactive protein. Comparison of T1 mapping with
these markers will identify whether it can provide
additional prognostic information. A simple bloodbiomarker is preferable to an expensive and lengthy
CMR in identiﬁcation of cardiac involvement, and its
additive value against blood markers therefore needs
to be established.
At a clinical level, it remains to be demonstrated
that an increased ECV portends worse outcome in RA.
The next step is therefore a prospective longitudinal
outcome study. On the basis of the current data from
other populations (13), one would expect this to be
the case, but it needs to be conﬁrmed. Finally,
assuming that this is the case, it would be important
to undertake CMR studies and serially monitor ECV
in patients “on” and “off” treatment to establish
whether additional therapies can alter ECV and im-
prove prognosis as well as identify potential ﬂuctua-
tions in ECV with disease activity. However,
“additional treatment” could arguably be immuno-
modulatory or cardioprotective in nature. We do not
know at present which option, if any, might reduce
ECV, and we need to investigate both avenues before
we can establish what would be most beneﬁcial for
the RA population. Some answers will come from the
CADERA (Coronary Artery Disease Evaluation in
Rheumatoid Arthritis) study, which is currently ac-
tively recruiting (14). Without a prospective outcome-
driven multicenter study involving a pharmacological
intervention showing beneﬁt, it would be difﬁcult to
fully embrace T1 mapping for prognostic purposes in
this cohort. To predict the future of patients with RA
by using T1 mapping, as Niels Bohr would put it, “is
difﬁcult;” however, that future is potentially bright.
At present, and while further supportive data
are awaited, the threshold of undertaking CMR in
RA patients could be appropriately lowered as the
combination of T1 mapping, T2-weighted imaging,
and LGE described by Ntusi et al. (6) can conﬁrm
silent coronary disease and identify early cardiac
involvement.
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